RTP Mobile Logo

Friday, December 6, 2019, Orlando, Florida, 12:30 PM – 3:30 PM

Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)

A Friday Satellite Symposium Preceding the 61st ASH Annual Meeting

This activity, the first of a 2-part series, will focus on common practical issues and challenges faced by clinicians caring for patients with lymphoma and chronic lymphocytic leukemia. Six world-renowned investigators will serve as the faculty. Leading up to the event, Research To Practice will recruit community-based medical and hematologic oncologists to participate in a unique assessment to identify specific challenging clinical situations or questions they have related to the management of these diseases for which they would seek investigator input. The live event will be divided into 6 distinct topic modules, each featuring a discussion of the questions and issues presented by the consulting clinicians and a faculty member-led review of relevant ongoing research. To cultivate a more interactive experience, clinicians in attendance will utilize networked iPads® to complete an onsite survey featuring a number of the same questions and topics to be discussed, the results of which will be presented and discussed throughout the program.

Event Details

Location
Hilton Orlando
6001 Destination Parkway
Orlando, FL 32819
Hotel Phone: (407) 313-4300

Time
12:30 PM – 1:00 PM — Registration and Lunch Buffet
1:00 PM – 3:30 PM — Educational Meeting

Meeting Room
Orange Ballroom (Lower Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty
Jeremy Abramson, MD
Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Bruce D Cheson, MD
Frank M Ewing Foundation Chair in
Hematology-Oncology
Professor of Medicine
Head of Hematology and Cellular Therapy
Deputy Chief, Division of Hematology-Oncology
Georgetown University Hospital
Lombardi Comprehensive Cancer Center
Washington, DC

Prof John G Gribben, MD, DSc, FMedSci
Chair of Medical Oncology
Barts Cancer Institute
Queen Mary University of London
Charterhouse Square
London, United Kingdom


Brad S Kahl, MD
Professor of Medicine
Washington University School of Medicine
Director, Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

Loretta Nastoupil, MD
Associate Professor
Department of Lymphoma/Myeloma
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Laurie H Sehn, MD, MPH
Chair, Lymphoma Tumour Group
BC Cancer Centre for Lymphoid Cancer
Associate Editor, Blood
Vancouver, Canada

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida



Agenda

Event Time
12:30 PM – 1:00 PM — Registration and Lunch Buffet
1:00 PM – 3:30 PM — Educational Meeting

MODULE 1: Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) — Dr Kahl

  • Implications of recent Phase III data comparing ibrutinib (with or without rituximab) to standard chemoimmunotherapy for younger (ECOG-E1912) and older (Alliance A041202) patients with treatment-naïve CLL
  • Results from the Phase III CLL14 trial evaluating venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for patients with treatment-naïve CLL and coexisting medical conditions; clinical implications of the recent FDA approval of this regimen
  • Outcomes from the Phase III iLLUMINATE trial comparing ibrutinib/obinutuzumab to chlorambucil/obinutuzumab for treatment-naïve CLL; recent FDA approval of ibrutinib/obinutuzumab and patient selection for its use
  • Clinical and biologic factors influencing the selection of first-line treatment regimen for patients with newly diagnosed CLL requiring active therapy
  • Emerging results from the Phase III ELEVATE-TN trial comparing obinutuzumab/chlorambucil, acalabrutinib/obinutuzumab and acalabrutinib for patients with previously untreated CLL; recent breakthrough therapy designation for acalabrutinib as monotherapy for CLL

MODULE 2: Management of Relapsed/Refractory (R/R) CLL and Novel Investigational Approaches — Prof Gribben

  • Long-term outcomes of the Phase III MURANO trial comparing venetoclax/rituximab to bendamustine/rituximab (BR) for R/R CLL
  • Key findings from the Phase III ASCEND trial comparing acalabrutinib to rituximab in combination with either idelalisib or bendamustine for patients with R/R CLL; ongoing Phase III ELEVATE-RR study of acalabrutinib versus ibrutinib for high-risk R/R disease
  • Key efficacy and safety outcomes from the Phase III DUO trial evaluating duvelisib versus ofatumumab for R/R CLL; FDA approval of duvelisib and optimal role of PI3 kinase inhibition in patients with R/R CLL
  • Ongoing randomized trials evaluating novel combination approaches for newly diagnosed CLL (eg, FLAIR, CLL13 [GAIA], CLL3011 [GLOW])
  • Potential role of minimal residual disease assessment to permit rational treatment discontinuation in patients with CLL

MODULE 3: Contemporary Management of Newly Diagnosed and R/R Follicular Lymphoma (FL) — Dr Cheson

  • Clinical and research implications of the Phase III RELEVANCE trial evaluating the “R-squared” regimen of lenalidomide/rituximab in newly diagnosed FL
  • Results from the Phase III AUGMENT trial comparing R-squared to rituximab monotherapy for patients with R/R indolent lymphomas; recent FDA approval of R-squared for previously treated FL and marginal zone lymphoma
  • Role of obinutuzumab-based induction and maintenance therapy for previously untreated FL; integration of obinutuzumab into current algorithms for treatment-naïve and R/R disease
  • Mechanistic similarities and differences between the commercially available PI3 kinase inhibitors copanlisib, duvelisib and idelalisib; patient selection for these agents
  • Ongoing investigation of novel agents in FL (eg, acalabrutinib, venetoclax)

MODULE 4: Protocol and Off-Protocol Care for Patients with Mantle Cell Lymphoma (MCL) — Dr Abramson

  • Early activity and safety data with ibrutinib alone or in combination with other systemic therapies for previously untreated MCL; ongoing and planned Phase III trials (eg, TRIANGLE, SHINE, SYMPATICO)
  • Clinical research data supporting the FDA approval of acalabrutinib in R/R MCL and patient selection for this approach in routine practice
  • Early activity, ongoing trials and current nonresearch role, if any, of venetoclax in R/R MCL
  • Rates of clinical and laboratory tumor lysis syndrome documented in patients with non-Hodgkin lymphoma receiving venetoclax; comparison to historical studies of venetoclax in CLL
  • Other promising agents and strategies under investigation in the front-line and R/R settings

MODULE 5: Recent Breakthroughs and Other Promising Approaches in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn

  • Clinical and research implications of trials evaluating lenalidomide-containing combination regimens for patients with DLBCL
  • Published findings from the Phase III PHOENIX study of ibrutinib in combination with R-CHOP for previously untreated nongerminal center B-cell DLBCL; variability of efficacy outcomes according to patient age and implications for future research
  • Available efficacy and safety data leading to the FDA approval of polatuzumab vedotin in combination with BR for patients with R/R DLBCL; optimal incorporation into current management algorithms
  • Early findings with polatuzumab vedotin in combination with R-CHP for patients with previously untreated DLBCL; ongoing Phase III POLARIX trial
  • Other promising agents or strategies under investigation for newly diagnosed and relapsed/refractory DLBCL (eg, venetoclax, tafasitamab)

MODULE 6: Integration of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Lymphomas — Dr Nastoupil

  • Compositional and mechanistic similarities and differences between available (axicabtagene ciloleucel [axi-cel], tisagenlecleucel [tis-cel]) and investigational (lisocabtagene maraleucel [liso-cel]) CD19-directed CAR T-cell platforms with established efficacy in DLBCL
  • Longer-term follow-up from clinical trials establishing the efficacy and safety of axi-cel, tis-cel and liso-cel
  • Patient identification and appropriate referral for consideration of CAR T-cell therapy
  • Current understanding of potential clinical and biologic factors predictive of response or toxicity to CAR T-cell therapy in patients with DLBCL or other aggressive lymphomas
  • Available data with and ongoing evaluation of CD19-directed CAR T-cell therapy in CLL and other lymphoma variants (eg, FL, MCL)

CE Information

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia (CLL).

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Review recent therapeutic advances and related FDA authorizations for newly diagnosed and relapsed/refractory mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and CLL, and use this information to counsel patients regarding protocol and off-protocol therapy.
  • Consider published Phase III efficacy and safety data evaluating the use of BTK (Bruton tyrosine kinase) inhibition as first-line therapy for patients with treatment-naïve CLL, and use this information to discern how, if at all, these strategies can be optimally integrated into nonresearch care algorithms.
  • Recall the biologic rationale for, available research evidence with and ongoing research efforts evaluating the use of chemotherapy-free combinations for newly diagnosed and progressive FL, CLL and MCL to prepare for their potential introduction into the practical management of these diseases.
  • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor (CAR) T-cell therapy, and identify patients with relapsed/refractory B-cell cancers for whom this approach may be appropriate.
  • Describe available and emerging data with other investigational agents and immunotherapeutic strategies currently under evaluation for MCL, DLBCL, FL and CLL, and where applicable, refer eligible patients for trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters
This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

Location

Hilton Orlando
6001 Destination Parkway
Orlando, FL 32819
Hotel Phone: (407) 313-4300

Meeting Room
Orange Ballroom (Lower Level)

Directions
The Hilton Orlando hotel is conveniently located within walking distance of the Orange County Convention Center, where the ASH Annual Meeting is taking place.

 

Registration

This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphomas and chronic lymphocytic leukemia.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.